company background image
INAF logo

Indofarma IDX:INAF Stock Report

Last Price

Rp126.00

Market Cap

Rp390.5b

7D

0%

1Y

-74.3%

Updated

28 Sep, 2024

Data

Company Financials

INAF Stock Overview

Manufactures and sells pharmaceutical products in Indonesia and internationally. More details

INAF fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health0/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

PT Indofarma Tbk Competitors

Price History & Performance

Summary of share price highs, lows and changes for Indofarma
Historical stock prices
Current Share PriceRp126.00
52 Week HighRp725.00
52 Week LowRp126.00
Beta-0.049
1 Month Change0%
3 Month Change0%
1 Year Change-74.29%
3 Year Change-94.50%
5 Year Change-90.74%
Change since IPO-38.54%

Recent News & Updates

Recent updates

Shareholder Returns

INAFID PharmaceuticalsID Market
7D0%-9.6%-3.6%
1Y-74.3%-23.0%2.7%

Return vs Industry: INAF underperformed the ID Pharmaceuticals industry which returned -1.3% over the past year.

Return vs Market: INAF underperformed the ID Market which returned 14.4% over the past year.

Price Volatility

Is INAF's price volatile compared to industry and market?
INAF volatility
INAF Average Weekly Movementn/a
Pharmaceuticals Industry Average Movement4.1%
Market Average Movement5.5%
10% most volatile stocks in ID Market12.8%
10% least volatile stocks in ID Market2.4%

Stable Share Price: INAF has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine INAF's volatility change over the past year.

About the Company

FoundedEmployeesCEOWebsite
1918900. Yeliandrianiindofarma.id

PT Indofarma Tbk, together with its subsidiaries, manufactures and sells pharmaceutical products in Indonesia and internationally. The company offers laboratory, pharmaceutical, and health glass equipment; orthopedic and prosthetic equipment; medical and dental equipment; and reparation of Irradiation / X-ray, electromedical and electrotherapy equipment. It also trades in laboratory, pharmaceutical, and medical equipment; and engages in herb infusion, health support, private polyclinic, general practitioner, dentist, and internet trading applications activities.

PT Indofarma Tbk Fundamentals Summary

How do Indofarma's earnings and revenue compare to its market cap?
INAF fundamental statistics
Market capRp390.51b
Earnings (TTM)-Rp702.59b
Revenue (TTM)Rp269.35b

1.4x

P/S Ratio

-0.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
INAF income statement (TTM)
RevenueRp269.35b
Cost of RevenueRp445.42b
Gross Profit-Rp176.06b
Other ExpensesRp526.52b
Earnings-Rp702.59b

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-226.69
Gross Margin-65.37%
Net Profit Margin-260.84%
Debt/Equity Ratio-81.2%

How did INAF perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/09/28 17:07
End of Day Share Price 2024/07/01 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

PT Indofarma Tbk is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yohan SetioPT Mandiri Sekuritas
Guntur HariyantoPT PEFINDO